Benzodiazepine Use and Long-Term Mortality in South Korean Adult Population: A Cohort Study

Tak Kyu Oh¹, Hye Youn Park², and In-Ae Song¹

Departments of ¹Anesthesiology and Pain Medicine, and ²Psychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.

INTRODUCTION

Benzodiazepine is a commonly prescribed psychoactive drug for the treatment of anxiety and sleep disorders.¹ It has been reported that 7.8% of the Dutch population aged 55–64 years and 5.2% of the United States (US) population aged 18–80 years use benzodiazepine.² In addition, the number of benzodiazepine prescriptions in the US increased from 1996 to 2013.³ As long-term benzodiazepine use causes dependence and addiction,⁴ benzodiazepine prescription presents public health burden and concern.⁵

Cohort studies before 2009 have reported mixed results on the association between benzodiazepine use and mortality.⁶ More recent epidemiological studies have reported that the risk of all-cause mortality in adult benzodiazepine users is higher than that in non-users, even when used for less than 1 month.⁷,⁸ In addition, several studies conducted in adult populations have not provided evidence for an increased risk of all-cause mortality with benzodiazepine use; however, the results have suggested associations with a wide range of causes of death, such as cancer, cardiovascular disease, respiratory diseases, and suicide.⁹,¹⁰ In 2017, Patorno, et al.¹¹ reported that there was no increase or a minor increase in the risk of all-cause mortality among benzodiazepine users compared to that in non-users in the US. However, information regarding the long-diazepine prescriptions in the US increased from 1996 to 2013.³

Purpose: Studies have reported mixed results on the association between benzodiazepine use and mortality. Here, we investigated whether benzodiazepine use is associated with a higher risk of 5-year all-cause mortality, and examined the association between benzodiazepine use and 5-year disease-specific mortality.

Materials and Methods: In this population-based cohort study, a nationally representative sample cohort in South Korea was examined. In 2010, benzodiazepine users were defined as individuals prescribed benzodiazepine continuously over 30 days for regular administration, and all other subjects were included in the control group. The primary endpoint was 5-year all-cause mortality, evaluated from 2011 to 2015. Propensity score (PS) matching and time-dependent Cox regression were performed for statistical analysis, which included benzodiazepine use during 2011–2015 as a time-dependent variable.

Results: A total of 822414 adult individuals were included in the final analysis, and the all-cause 5-year mortality was recorded in 20991 individuals (2.7%). The benzodiazepine group included 30837 patients and the control group comprised 791377 patients. After PS matching, 61672 individuals (30836 in each group) were included in the final analysis. After PS matching, the 5-year all-cause mortality in the benzodiazepine group was 10.0% (3082/30836), whereas that in the control group was 9.4% (2893/30836). In time-dependent Cox regression analysis of the PS-matched cohort, the benzodiazepine group showed 1.15-fold higher 5-year all-cause mortality (hazard ratio: 1.15, 95% confidence interval: 1.09–1.22; p<0.001) compared to the control group.

Conclusion: Benzodiazepine use was associated with increased 5-year all-cause mortality in the South Korean adult population. Further studies are needed to confirm these findings.

Key Words: Benzodiazepine, mortality, population
term all-cause mortality and disease-specific mortality based on exposure to benzodiazepine is still lacking, necessitating more studies.

Therefore, the present study aimed to investigate whether benzodiazepine use is associated with a higher risk of 5-year all-cause mortality in the adult population in South Korea. Additionally, we examined the association between benzodiazepine use and 5-year disease-specific mortality.

**MATERIALS AND METHODS**

**Design and ethical concerns**

The present population-based cohort study was conducted in accordance with the Reporting of Observational Studies in Epidemiology guidelines. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (X-1905-541-903) and Health Insurance Review and Assessment Service. The requirement for informed consent was waived due to the retrospective nature of the study, which involved the use of anonymized data extracted from the South Korean National Health Insurance Service (NHIS) database.

**Data source: NHIS sample cohort**

The sample cohort of the NHIS database was developed to provide health-related data for medical research in the South Korean population. The database was created from a random stratified sample of approximately one million people registered under the NHIS in 2002, and was designed to be demographically and socioeconomically representative of the national population of South Korea. The cohort was dynamic and was followed up until the end of 2015. Additional cohort data, including those of infants, were analyzed to allow for attrition due to death and follow-up loss. Using stratified extraction methods, individuals were added to the cohort annually to replace those who had died or emigrated in the previous year. This was performed to ensure that the cohort continued to represent the national population in terms of demographic and socioeconomic status of the South Korean population. The sample cohort database included information on individuals’ demographic characteristics, socioeconomic status, healthcare use, medical history, and cause of death.15

**Study population**

We included all adult patients (age ≥18 years) in the 2010 NHIS sample cohort. We then excluded individuals who died in 2010 and those who moved out of the country between 2011 and 2015, as benzodiazepine prescription information was no longer available after emigration.

**Exposure variable: benzodiazepine use**

The prescription data of medication during 2010–2015 were extracted for this study. Using the prescription data of benzodiazepine in 2010, benzodiazepine users were defined as individuals who were prescribed benzodiazepine continuously over 30 days for regular intake. All other subjects were included in the control group; for example, individuals who had never been prescribed benzodiazepine and those who had been prescribed benzodiazepine for <30 days were included in the control group. Benzodiazepines included alprazolam, clonazepam, chlordiazepoxide, diazepam, lorazepam, and triazolam in the present study.

**Study endpoint**

The primary endpoint was the 5-year all-cause mortality. As we excluded individuals who died in 2010 from the analytic cohort, survival time and mortality were assessed from January 1, 2011 to December 31, 2015. In addition, we evaluated the 5-year disease-specific mortality, which was classified based on the main diseases causing death according to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) codes. In particular, we considered 5-year cancer (C00-D48), cardiovascular disease (I00-I99), respiratory diseases (J00-J99), digestive diseases (K00-K93), infectious and parasitic diseases (A00-B99), endocrine and metabolic diseases (E00-E90), nervous system diseases (G00-G99), musculoskeletal disease-related mortality (M00-M99), and injury- and poisoning-related mortality (S00-T98).

**Confounders**

Data on the following variables were collected as confounders: 1) demographic information (age and sex); 2) socioeconomic information [income level in five groups, and place of residence in 2010 (Seoul, metropolitan cities, or others)]; 3) Charlson comorbidity index, which was calculated using the registered ICD-10 diagnostic codes between 2009 and 2010 in the NHIS database (Supplementary Table 1, only online); and 4) the number of outpatient clinic visits in 2010 (day). Data on the number of outpatient clinic visits were collected in the study to reflect frailty in individuals, and were divided into four groups (0–7, 8–30, 31–90, and >90 days).

**Statistical analysis**

The demographic and clinical characteristics of all individuals are presented as mean with standard deviation for continuous variables and number with percentage for categorical variables. First, we performed 1:1 propensity score (PS) matching between the benzodiazepine and control groups to reduce the possibility of bias in observational study.16 For PS matching, the nearest neighbor method was used without replacement with a caliper of 0.25. All covariates were included in PS modeling, and logistic regression was used to calculate PS in the PS model. The absolute value of the standardized mean difference (ASD) was used to evaluate the balance between groups before and after PS matching. The ASD was set at <0.1 to
confirm adequate balance between the groups. After confirming the adequate balance between groups through PS matching, we performed time-dependent Cox regression analysis,17 as our study focused on time-dependent exposure to benzodiazepine use in the 2010 cohort between 2011 and 2015. To confirm whether benzodiazepine exposure varied during 2011–2015, we investigated the proportion of benzodiazepine users who discontinued benzodiazepine therapy or commenced it during the evaluation period, that is, 2011–2015. The results revealed that exposure to benzodiazepine therapy varied between the benzodiazepine users and controls throughout the evaluation period (Supplementary Table 2, only online). Therefore, exposure to benzodiazepine prescription was considered a time-dependent variable, and all-cause death from January 1, 2011 to December 31, 2015 was set as the event in the time-dependent Cox model of the PS-matched cohort. Next, we constructed nine time-dependent Cox regression models to investigate whether benzodiazepine use was associated with specific disease-related 5-year mortality in the PS-matched cohort. The nine disease-specific 5-year mortalities were used as endpoints in each model. Correction for multiple comparisons was not performed to reduce the chances of missing important associations. In addition, 1:1 PS matching identification was not included in the models as a random intercept in this study.

For sensitivity analysis, in addition to analyses of the PS-matched cohort, we fit a multivariable time-dependent Cox regression model for 5-year all-cause mortality in the entire cohort to determine whether the results obtained from the PS-matched cohort were generalizable to the entire cohort. In the multivariable time-dependent Cox regression model, benzodiazepine exposure from 2011 to 2015 was included as a time-dependent variable, while all other covariates were included in the model as time-fixed covariates. Finally, we performed subgroup analyses according to age to examine whether similar hazard ratios (HRs) were estimated for each age group (<40, 40–60, and >60 years). Multivariable time-dependent Cox regression modeling was used for the subgroup analyses. The results of the Cox regression models are presented as HR with 95% confidence interval (CI). All multivariable models of the entire cohort were confirmed to have no multicollinearity (variance inflation factor <2.0). All statistical analyses were performed using R version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria). Results with p-values <0.05 were considered statistically significant.

RESULTS

The 2010 NHIS sample cohort comprised 826909 adult individuals. We excluded 4487 individuals who died in 2010 and 208 who moved out of South Korea between 2011 and 2015. As a result, 822414 adult individuals were included in the final

---

**Fig. 1. Flow chart of participant selection.**

---
analysis, and the all-cause 5-year mortality was observed in 20991 (2.7%) individuals. The benzodiazepine group comprised 30837 (3.8%) individuals and the control group comprised 791377 (96.2%) individuals. After PS matching, 61672 individuals (30836 in each group) were included in the final analysis (Fig. 1). The results of the comparison of demographic and clinical characteristics between the benzodiazepine and control groups before and after PS matching are presented in Table 1. After PS matching, all ASDs between the groups were below 0.1, suggesting adequate balance through PS matching.

**Table 1. Comparison of Baseline Characteristics between Benzodiazepine Users and Controls Before and After PS Matching**

| Variable                          | Before PS matching | After PS matching | ASD   | Before PS matching | After PS matching | ASD   |
|-----------------------------------|--------------------|-------------------|-------|--------------------|-------------------|-------|
|                                   | Benzodiazepine users n=30837 | Controls n=791377 | ASD   | Benzodiazepine users n=30836 | Controls n=30836 | ASD   |
| Age, yr                           | 60.6 (14.5)        | 43.9 (15.9)       | 0.271 | 60.6 (14.5)        | 60.0 (15.6)       | 0.026 |
| Sex, male                         | 11408 (37.0)       | 396379 (50.1)     | 1.154 | 11408 (37.0)       | 11795 (38.3)      | 0.038 |
| Annual income level in 2020       |                    |                   |       |                    |                   |       |
| 1st (lowest income level)         | 4133 (13.4)        | 109392 (13.8)     | 0.116 | 3843 (12.5)        | 3872 (12.6)       | 0.003 |
| 2nd                               | 3843 (12.5)        | 128945 (16.3)     | 0.039 | 3843 (12.5)        | 3872 (12.6)       | 0.004 |
| 3rd                               | 7367 (23.9)        | 175795 (22.2)     | 0.028 | 6339 (20.6)        | 6386 (20.7)       | 0.004 |
| 4th                               | 6340 (20.6)        | 171731 (21.7)     | 0.081 | 9154 (29.7)        | 9208 (29.9)       | 0.004 |
| 5th (highest income level)        | 9154 (29.7)        | 205514 (26.0)     | 0.014 | 11408 (37.0)       | 396379 (50.1)     | 0.026 |
| Residence at 2010                 |                    |                   |       |                    |                   |       |
| Capital city (Seoul)              | 5486 (17.8)        | 163387 (21.4)     | 0.004 | 5486 (17.8)        | 5422 (17.6)       | 0.007 |
| Metropolitan city                 | 7813 (25.3)        | 201943 (25.5)     | 0.014 | 7812 (25.3)        | 7900 (25.6)       | 0.007 |
| Others                            | 17536 (56.9)       | 420047 (53.1)     | 0.077 | 17536 (56.9)       | 17514 (56.8)      | 0.002 |
| Charlson comorbidity index        | 3.1 (2.4)          | 1.1 (1.6)         | 0.833 | 3.1 (2.4)          | 3.0 (2.5)         | 0.057 |
| Hypertension                      | 16413 (53.2)       | 131316 (16.6)     | 0.734 | 16412 (53.2)       | 16073 (52.1)      | 0.014 |
| Myocardial infarction             | 1122 (3.6)         | 5982 (0.8)        | 0.154 | 1121 (3.6)         | 1038 (3.4)        | 0.030 |
| Congestive heart failure          | 290 (9.5)          | 13910 (1.7)       | 0.225 | 2929 (9.5)         | 2588 (8.4)        | 0.038 |
| Peripheral vascular disease       | 8529 (27.7)        | 56881 (7.1)       | 0.461 | 8528 (27.7)        | 8111 (26.3)       | 0.030 |
| Cerebrovascular disease           | 7965 (25.9)        | 36223 (4.6)       | 0.487 | 7964 (25.9)        | 7357 (23.9)       | 0.046 |
| Peptic ulcer disease              | 16971 (55.0)       | 178223 (22.5)     | 0.654 | 16970 (55.0)       | 16444 (53.3)      | 0.034 |
| DM without chronic complication   | 9294 (30.1)        | 75382 (9.5)       | 0.449 | 9293 (30.1)        | 9007 (29.2)       | 0.020 |
| DM with chronic complication      | 4129 (13.4)        | 29532 (3.7)       | 0.284 | 4128 (13.4)        | 3857 (12.5)       | 0.026 |
| Renal disease                     | 624 (2.0)          | 5136 (0.6)        | 0.098 | 624 (2.0)          | 570 (1.8)         | 0.012 |
| Dementia                          | 406 (1.3)          | 1458 (0.2)        | 0.099 | 406 (1.3)          | 353 (1.1)         | 0.015 |
| Hemiplegia or paraplegia          | 801 (2.6)          | 4415 (0.6)        | 0.128 | 789 (2.6)          | 748 (2.4)         | 0.010 |
| Rheumatic disease                 | 2843 (9.2)         | 22277 (2.8)       | 0.222 | 2844 (9.2)         | 2707 (8.8)        | 0.015 |
| Mild liver disease                | 11673 (37.9)       | 129414 (15.6)     | 0.459 | 11672 (37.9)       | 11370 (36.9)      | 0.020 |
| Moderate to severe liver disease  | 533 (1.7)          | 5395 (0.7)        | 0.080 | 533 (1.7)          | 502 (1.6)         | 0.008 |
| Chronic pulmonary disease         | 13998 (45.4)       | 188136 (23.8)     | 0.434 | 13997 (45.4)       | 13632 (44.2)      | 0.024 |
| Any cancer                        | 3092 (10.0)        | 27745 (3.5)       | 0.217 | 3091 (10.0)        | 2965 (9.6)        | 0.014 |
| Metastatic solid tumor            | 324 (1.1)          | 3370 (0.4)        | 0.061 | 324 (1.1)          | 316 (1.0)         | 0.003 |
| Outpatient clinic visit in 2010, day |                |                   |       |                    |                   |       |
| 0–7                               | 309 (12.0)         | 501749 (63.4)     | 0.271 | 309 (12.0)         | 3924 (12.7)       | 0.024 |
| 8–30                              | 13979 (48.4)       | 261473 (33.0)     | 0.650 | 13979 (48.4)       | 20142 (65.3)      | 0.024 |
| 31–90                             | 7168 (23.2)        | 27662 (3.5)       | 0.468 | 7167 (23.2)        | 6636 (21.5)       | 0.041 |
| >90                               | 168 (0.5)          | 495 (0.1)         | 0.066 | 168 (0.5)          | 134 (0.4)         | 0.015 |

PS, propensity score; ASD, absolute value of standardized mean difference; DM, diabetes mellitus.

Presented as mean value with standard deviation or number with percentage.

**Main analysis after PS matching**

Table 2 shows the results of survival analyses before and after PS matching. After PS matching, the 5-year all-cause mortality in the benzodiazepine group was 10.0% (30836/30836), whereas in the control group was 9.4% (2893/30836). In the time-dependent Cox regression model of the PS-matched cohort, the benzodiazepine group showed 1.15-fold higher 5-year all-cause mortality (HR: 1.15, 95% CI: 1.09–1.22; p<0.001) compared to the control group. The analysis results of the disease-specific time-dependent Cox regression models of the PS-
matched cohort are presented in Table 3. The 5-year nervous system disease-related mortality in the benzodiazepine group was the highest (HR: 2.09, 95% CI: 1.55–2.81; \( p < 0.001 \)), compared to that in the control group. The risks of 5-year digestive disease mortality and injury- and poisoning-related mortality in the benzodiazepine group were 1.53-fold (HR: 1.53, 95% CI: 1.17–2.00; \( p = 0.002 \)) and 1.42-fold higher than those in the control group (HR: 1.42, 95% CI: 1.17–1.73; \( p < 0.001 \)), respectively.

The 5-year mortalities due to cancer \( (p=0.511) \), respiratory diseases \( (p=0.524) \), endocrine and metabolic diseases \( (p=0.083) \), infectious and/or parasitic diseases \( (p=0.434) \), and musculoskeletal diseases \( (p=0.962) \) were not associated with benzodiazepine use.

Sensitivity and subgroup analyses in the entire cohort

Table 4 shows the analysis results of the multivariable time-dependent Cox regression model for 5-year all-cause mortality in the entire cohort. In the model, the benzodiazepine group showed 1.22-fold higher 5-year all-cause mortality compared to the control group (HR: 1.22, 95% CI: 1.17–1.28; \( p < 0.001 \)).

Table 5 shows the results of subgroup analyses according to age using the multivariable time-dependent Cox regression model. In the subgroup analyses, the benzdiazepine group showed the highest HR for 5-year all-cause mortality in the <40 year group (HR: 2.00, 95% CI: 1.39–2.87; \( p < 0.001 \)), followed by the 40–60 year group (HR: 1.45, 95% CI: 1.28–1.63; \( p < 0.001 \)) and >60 year group (HR: 1.23, 95% CI: 1.17–1.28; \( p < 0.001 \)).

**DISCUSSION**

This population-based cohort study showed that benzodiazepine use was associated with a higher risk of 5-year all-cause mortality in the South Korean adult population. Among disease-
specific mortalities, benzodiazepine use exhibited the highest risk for nervous system disease-related mortality. Additionally, benzodiazepine use was not associated with mortality due to cancer, infectious and/or parasitic diseases, respiratory diseases, endocrine and metabolic diseases, or musculoskeletal diseases. In addition, our subgroup analyses showed that the association between benzodiazepine use and increased 5-year all-cause mortality was most evident in the younger population, that is, those <40 years old.

A previous study reported that benzodiazepine users had a higher risk for all-cause mortality than non-users in two large cohort studies in France and the UK. The study focused on the risk for all-cause mortality for up to 12 months, whereas our study examined the 5-year all-cause mortality. Another retrospective longitudinal study reported that benzodiazepine use was associated with an increase in all-cause mortality based on a time-dependent Cox model. The study analyzed patients with schizophrenia, whereas we focused on the general adult population in South Korea. Conversely, a recent large prospective cohort study in the US reported that the initiation of benzodiazepine prescription was not associated with mortality over an observation period of up to 6 months. However, in a sensitivity analysis with a follow-up period of 48 months, the mortality was increased by 4% in benzodiazepine users compared to that in non-users (HR: 1.04, 95% CI: 1.02–1.07), suggesting that benzodiazepine exposure can influence the relative long-term all-cause mortality, as observed in our study. Therefore, recent evidence suggests that the all-cause and long-term mortality might be increased in benzodiazepine-users compared to those in non-users.

In the disease-specific Cox proportional hazard models, the 5-year mortality due to nervous system diseases was most closely associated with benzodiazepine use in the present study. It might be influenced by the indication of benzodiazepine prescription, as benzodiazepines have been prescribed for various indications such as anxiety, insomnia, and epilepsy. Such diseases, which are indications for benzodiazepine, are closely related to disorders in the central nervous system. Therefore, benzodiazepine users could have suffered from neurological disorders in the present study, and this could have led to the increased 5-year nervous system disease-related mortality in our study. In this regard, a previous study reported that a higher mortality rate was associated with benzodiazepine use in individuals with Alzheimer’s disease.

Previous studies have suggested an association between benzodiazepine use and a wide range of causes of death, such as cancer and cardiovascular disease. While our study showed that benzodiazepine use was associated with a higher risk of cardiovascular disease, the 5-year cancer mortality was not associated with benzodiazepine use. The issue regarding the association between cancer risk and benzodiazepine exposure has been controversial. Although recent meta-analyses have suggested a positive association between benzodiazepine exposure and cancer risk, the most recently published meta-analysis reported that the use of lower dose hypnotics and shorter durations of exposure to benzodiazepines do not seem to be associated with an increased risk of cancer. Additionally, a dose-response relationship between benzodiazepine exposure and cancer risk has been suggested. Since we did not evaluate the effect of the dosage of benzodiazepine, the result regarding 5-year cancer mortality should be interpreted with caution, and additional studies should be performed.

The results of the subgroup analyses according to age were significant in this study. Previous studies have reported that benzodiazepine use is associated with a higher risk of mortality among older adults. However, information regarding the relationship between benzodiazepine use and mortality among young adults is still lacking. In the US, benzodiazepine dependence and misuse among young adults are important social and public health issues. Another previous study reported that the misuse rate of benzodiazepine was the highest in young adults and the lowest in older individuals in the US. The misuse or abuse of benzodiazepine is known to be associated with a higher risk of both mortality and suicide. In our study, the misuse of benzodiazepine in young adults might have affected the results. However, information regarding this issue is still lacking, and more research is needed to confirm the relationship between benzodiazepine use and mortality risk among young adults.

This study had some limitations. First, some important physiologic variables, such as body mass index, were not included in the analysis since relevant data were not available in the NHIS database. Furthermore, we used the ICD-10 codes registered in the NHIS database to calculate the Charlson comorbidity indices. However, some of the underlying diseases specified using the codes might not reflect the actual underlying diseases. Lastly, we used PS modeling or multivariable time-dependent Cox regression modeling to adjust for confounders in the present study; however, there might be residual and unmeasured confounders, which might have affected the results of the present study.

In conclusion, benzodiazepine use was associated with increased 5-year all-cause mortality in the South Korean adult population. This association was most evident in the young adult population aged <40 years. In addition, benzodiazepine use was associated with the 5-year nervous system disease-related mortality. Further studies are needed to confirm these findings.

**AUTHOR CONTRIBUTIONS**

Conceptualization: Tak Kyu Oh and In-Ae Song. Data curation: Hye Youn Park. Formal analysis: Tak Kyu Oh. Investigation: Tak Kyu Oh and In-Ae Song. Methodology: Tak Kyu Oh and In-Ae Song. Project administration: In-Ae Song. Supervision: Tak Kyu Oh and In-Ae Song. Writing—original draft: Tak Kyu Oh. Writing—review & editing: Hye Youn Park and In-Ae Song. Approval of final manuscript: all authors.

https://doi.org/10.3349/ymj.2021.62.6.528
REFERENCES

1. Schmitz A. Benzodiazepine use, misuse, and abuse: a review. Ment Health Clin 2016;6:120-6.
2. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015;72:136-42.
3. Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. Am J Public Health 2016;106:686-8.
4. Soyka M. Treatment of benzodiazepine dependence. N Engl J Med 2017;376:1147-57.
5. Airagnes G, Lemogne C, Renuy A, Goldberg M, Hoertel N, Roqueaury Y, et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTATNES cohort. BMC Public Health 2019;19:566.
6. Charlson F, Degenhardt L, McLaren J, Hall W, Lynskey M. A systematic review of research examining benzodiazepine-related mortality. Pharmacoepidemiol Drug Saf 2009;18:93-103.
7. Kriple DE, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012;2:e000850.
8. Weich S, Pearce HL, Croft P, Singh S, Crome I, Bashford J, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. BMJ 2014;348:g1996.
9. Kriple DF, Klauber MR, Wingard DL, Fell RL, Assmus JD, Garfinkel L. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998;43:687-93.
10. Tiihonen J, Suokas JT, Swissaari JM, Haukja J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012;69:476-83.
11. Belleville G. Mortality hazard associated with anxiolytic and hypnotic drug use in the National Population Health Survey. Can J Psychiatry 2010;55:558-67.
12. Mallon L, Broman JE, Hetta J. Is usage of hypnotics associated with mortality? Sleep Med 2009;10:279-86.
13. Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1982;340:1067-8.
14. Patorno E, Glynn RJ, Levin R, Lee MP, Huybrechts KF. Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ 2017;358:j2941.
15. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol 2017;46:e15.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
17. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999;20:145-57.
18. Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur Neuropsychopharmacol 2015;25:1566-77.
19. Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, et al. Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 2016;77:661-7.
20. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013;13:214-23.
21. Lader M. Benzodiazepines. A risk-benefit profile. CNS Drugs 1994;1:377-87.
22. Saarelainen L, Tolppanen AM, Koponen M, Tanskanen A, Tiihonen J, Hartikainen S, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. Int J Geriatr Psychiatry 2018;33:583-90.
23. Kim DH, Kim HB, Kim YH, Kim JY. Use of hypnotics and risk of cancer: a meta-analysis of observational studies. Korean J Fam Med 2018;39:211-8.
24. Kim HB, Myung SK, Park YC, Park B. Use of benzodiazepine and risk of cancer: a meta-analysis of observational studies. Int J Cancer 2017;140:513-25.
25. Peng TR, Yang LJ, Wu TW, Chao YC. Hypnotics and risk of cancer: a meta-analysis of observational studies. Medicine (Kaunas) 2020;56:513.
26. Gisev N, Hartikainen S, Chen TF, Korhonen M, Bell JS. Mortality associated with benzodiazepines and benzodiazepine-related drugs among community-dwelling older people in Finland: a population-based retrospective cohort study. Can J Psychiatry 2011;56:377-81.
27. Jaussent I, Ancelin ML, Berr C, Pérès K, Scali J, Besset A, et al. Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Med 2013;11:212.
28. Vinkers DJ, Gussekloo J, van der Mast RC, Zitman FG, Westendorp RG. Benzodiazepine use and risk of mortality in individuals aged 85 years or older. JAMA 2003;290:2942-3.
29. Kurtz SP, Buttram ME, Surratt HL. Benzodiazepine dependence among young adult participants in the club scene who use drugs. J Psychoactive Drugs 2017;49:39-46.
30. Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv 2019;70:97-106.
31. Calcaterra SL, Severson SG, Bau GE, Margolin ZR, Bucher-Bartelson B, Green JL, et al. Trends in intentional abuse or misuse of benzodiazepines and opioid analgesics and the associated mortality reported to poison centers across the United States from 2000 to 2014. Clin Toxicol (Phila) 2018;56:1107-14.
32. Cato V, Holländare F, Nordenskjöld A, Sellin T. Association between benzodiazepines and suicide risk: a matched case-control study. BMC Psychiatry 2019;19:317.